23andMe’s founder Anne Wojcicki wins bid for – Business News
Anne Wojcicki is set to regain control of 23andMe after a nonprofit she controls topped Regeneron Pharmaceuticals’ bid for the DNA-testing company for $305 million as half of a chapter public sale.
Last month, Regeneron agreed to buy the firm for $256 million, topping a $146 million bid from Wojcicki and TTAM Research Institute.
“The agreement with non-profit TTAM Research Institute is the result of a final round of bidding that occurred earlier today between TTAM and Regeneron Pharmaceuticals,” the company mentioned in a assertion.
A nonprofit managed by former CEO Anne Wojcicki topped Regeneron’s bid for 23andMe. Getty Images
South San Francisco, Calif.-based 23andMe filed for chapter in March, in search of to sell its business at public sale after a decline in shopper demand and a 2023 information breach that uncovered delicate genetic and personal data of hundreds of thousands of prospects.
23andMe filed for chapter in March, in search of to sell its business at public sale after a decline in shopper demand and a 2023 information breach. REUTERS
23andMe, as soon as a trailblazer in ancestry DNA testing, has additionally confronted dwindling demand for its core companies.
